Efficacy and Safety of CyberKnife in the Treatment of Retroperitoneal Lymph Node Metastatic Carcinoma
Shuangyi Sun, Yun Guan, Yunwen Lu, Xiaoxia Liu, Bin Lv, Jing LiIntroduction
Retroperitoneal lymph node metastases represent a difficult clinical scenario in which durable local control must be balanced against the risk of radiation-induced toxicity to adjacent critical structures. The present study aimed to evaluate the efficacy and safety of CyberKnife treatment for retroperitoneal lymph node metastatic carcinoma.
Methods
This single-center retrospective cohort study included 34 patients with retroperitoneal lymph node metastatic carcinoma who received CyberKnife treatment at Huashan Hospital Fudan University from January 2018 to November 2022. Treatment was delivered with palliative local intent. Safety, short-term radiographic response, and survival outcomes were summarized.
Results
The median tumor volume was 35.8 (17.4-198) cm 3 . The total radiation dose was 19.2-45 Gy, delivered in 3-10 fractions with either continuous irradiation or intervals. The median biologically effective dose (BED, α/β=10) was 48.0 (28.4-67.1) Gy. No adverse reactions of grade 3 or above involving the gastrointestinal tract or myelosuppression were observed. The 3-month local control rate was 97%, with 3 lesions achieving complete response, 19 lesions achieving partial response, and 12 lesions maintaining stable disease. The median progression free survival was 8 months, and the median overall survival time was 13 (3-47) months.
Conclusion
CyberKnife treatment is safe and effective for retroperitoneal lymph node metastatic carcinoma, and some patients can achieve long-term survival.